高级检索
中华口腔医学杂志
期刊首页
过刊列表
高级检索
稿件发表
• 口腔黏膜病学研究 •
ENGLISH ABSTRACT
血清甲状腺抗体对口腔扁平苔藓治疗方案选择意义的初步探讨
刘传霞
陈方曼
张珊珊
唐帆
章尚君
钱韵
陈谦明
作者及单位信息
·
DOI： 10.3760/cma.j.cn112144-20241216-00487
Preliminary study on the significance of serum thyroid antibody in the selection of treatment for oral lichen planus
Liu Chuanxia
Chen Fangman
Zhang Shanshan
Tang Fan
Zhang Shangjun
Qian Yun
Chen Qianming
Authors Info & Affiliations
Liu Chuanxia
Department of Oral Medicine, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine & Clinical Research Center for Oral Diseases of Zhejiang Province & Key Laboratory of Oral Biomedical Research of Zhejiang Province & Cancer Center of Zhejiang University & Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou 310005, China
Chen Fangman
Department of Oral Medicine, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine & Clinical Research Center for Oral Diseases of Zhejiang Province & Key Laboratory of Oral Biomedical Research of Zhejiang Province & Cancer Center of Zhejiang University & Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou 310005, China
Zhang Shanshan
Department of Oral Medicine, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine & Clinical Research Center for Oral Diseases of Zhejiang Province & Key Laboratory of Oral Biomedical Research of Zhejiang Province & Cancer Center of Zhejiang University & Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou 310005, China
Tang Fan
Department of Oral Medicine, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine & Clinical Research Center for Oral Diseases of Zhejiang Province & Key Laboratory of Oral Biomedical Research of Zhejiang Province & Cancer Center of Zhejiang University & Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou 310005, China
Zhang Shangjun
Department of Oral Medicine, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine & Clinical Research Center for Oral Diseases of Zhejiang Province & Key Laboratory of Oral Biomedical Research of Zhejiang Province & Cancer Center of Zhejiang University & Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou 310005, China
Qian Yun
Department of Clinical Laboratory, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine & Clinical Research Center for Oral Diseases of Zhejiang Province & Key Laboratory of Oral Biomedical Research of Zhejiang Province & Cancer Center of Zhejiang University & Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou 310005, China
Chen Qianming
Department of Oral Medicine, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine & Clinical Research Center for Oral Diseases of Zhejiang Province & Key Laboratory of Oral Biomedical Research of Zhejiang Province & Cancer Center of Zhejiang University & Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou 310005, China
·
DOI： 10.3760/cma.j.cn112144-20241216-00487
255
30
0
0
1
3
PDF下载
APP内阅读
摘要

目的初步探讨口腔扁平苔藓（OLP）伴甲状腺抗体阳性患者不同治疗方案的疗效及其与甲状腺抗体滴度的相关性，以期为伴甲状腺抗体阳性的OLP患者提供更有针对性的诊疗方案。

方法纳入2020年2月至2024年6月于浙江大学医学院附属口腔医院口腔内科中心因OLP就诊，且做过甲状腺过氧化物酶抗体（TPOAb）和甲状腺球蛋白抗体（TGAb）血清检测的患者。记录人口学资料及临床信息，收集患者TPOAb及TGAb的定性状况及其定量滴度。将TPOAb和（或）TGAb阳性患者纳入抗体阳性组，TPOAb及TGAb均阴性患者纳入抗体阴性组。根据治疗方案分为局部治疗组、局部治疗联合口服免疫抑制剂组、局部治疗联合口服免疫增强剂组。分别于治疗后2周、1个月比较抗体阳性组与抗体阴性组不同治疗方案的临床疗效，并分析不同临床疗效与年龄、性别、甲状腺抗体滴度的相关性。

结果本研究共纳入116例OLP患者，其中抗体阳性组患者38例（32.8%），抗体阴性组患者78例（67.2%）。与治疗前相比，局部治疗以及局部治疗联合口服免疫抑制治疗后2周、1个月，抗体阴性组患者的改良OLP评分和疼痛程度显著改善（均 P<0.01），而抗体阳性组患者虽有缓解趋势，但治疗前后相比差异均无统计学意义（均 P>0.05）。局部治疗联合口服免疫增强剂者，治疗后2周和1个月抗体阳性组和抗体阴性组患者改良OLP评分和疼痛程度与治疗前相比差异均有统计学意义（ P<0.01），且两组间疗效差异无统计学意义（ P>0.05）。多因素Logistic回归分析显示，OLP在局部治疗组、局部治疗联合口服免疫抑制剂组、局部治疗联合口服免疫增强剂组的疗效与年龄、性别、TPOAb滴度、TGAb滴度均无显著相关性（ P>0.05）。

结论甲状腺抗体TPOAb、TGAb可作为OLP治疗方案选择的参考因素；OLP伴甲状腺抗体阳性患者，可优先选择局部治疗联合口服免疫增强剂的治疗方案。

扁平苔藓，口腔;甲状腺炎;桥本甲状腺炎;甲状腺过氧化物酶抗体;甲状腺球蛋白抗体;临床疗效
ABSTRACT

ObjectiveTo investigate the efficacy of different treatment of oral lichen planus (OLP) patients with thyroid antibody positive and its correlation with thyroid antibody, providing more targeted treatment for OLP patients with thyroid antibody positive.

MethodsPatients who were admitted to Department of Oral Medicine, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine for OLP with serum thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TGAb) from February 2020 to June 2024 were included. Demographic and clinical data were recorded, and qualitative status and quantitative titers of TPOAb/TGAb were collected. TPOAb and/or TGAb positive patients were included into the thyroid antibody positive group, while patients with both TPOAb and TGAb negative were included into the thyroid antibody negative group. According to the treatment methods, they were divided into topical treatment group, topical treatment combined with oral immunosuppressant group, and topical treatment combined with oral immunoenhancer group. After 2 weeks and 1 month of treatment, the clinical efficacy of thyroid antibody positive group and negative group in OLP patients under different treatment methods were compared, and the correlations of different clinical efficacy with age, sex and thyroid antibody titer were analyzed.

ResultsA total of 116 OLP patients were included in this study, of which 38 (32.8%) were thyroid antibody positive and 78 (67.2%) were thyroid antibody negative. Compared with untreated, the modified OLP score and pain degree in thyroid antibody negative group were significantly improved after 2 weeks and 1 month of topical treatment and topical treatment combined with oral immunosuppression ( P<0.01). Although the thyroid antibody positive group also showed a remission trend, there was no statistical significance before and after treatment ( P>0.05). For topical treatment combined with oral immunoenhancer, the modified OLP score and pain degree in both groups of antibody positive and negative were statistically significant different after 2 weeks and 1 month of treatment compared with before ( P<0.01), while there was no statistically significant difference between the two groups ( P>0.05). Multivariate Logistic regression analysis showed that the treatment efficacy of OLP in topical treatment group, topical treatment combined with oral immunosuppressant group, and topical treatment combined with oral immunoenhancer group had no significant correlation with age, sex, as well as the TPOAb and TGAb titer ( P>0.05).

ConclusionsThyroid antibody TPOAb and TGAb could be reference factors for the selection of OLP treatment plan. For patients of OLP with positive thyroid antibodies, topical therapy combined with oral immunoenhancers may be preferred.

Lichen planus, oral;Thyroiditis;Hashimoto thyroiditis;Thyroid peroxidase antibody;Thyroglobulin antibody;Clinical effect
Chen Qianming, Email: nc.defudabe.ujznehcmq, Tel: 0086-571-87217001

clinicalTrials.gov (NCT05403216)

Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

刘传霞,陈方曼,张珊珊,等. 血清甲状腺抗体对口腔扁平苔藓治疗方案选择意义的初步探讨[J]. 中华口腔医学杂志,2025,60(03)：223-231.

DOI:10.3760/cma.j.cn112144-20241216-00487

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

口腔扁平苔藓（oral lichen planus，OLP）是一种较常见的慢性炎症性口腔黏膜病，患病率为0.1%~4.0% ［ 1 , 2 ］ 。OLP好发于中年女性，患病率为男性的3~4倍 ［ 3 ］ 。OLP在口腔内主要表现为对称性分布的稍高于黏膜表面的白色或灰白色网纹，伴或不伴糜烂、疱、萎缩等表征，可分为网状型、糜烂型、萎缩型、斑块型、丘疹型和水疱型共6种临床类型。OLP主要累及颊、舌、牙龈等口腔黏膜，还可伴发指（趾）甲、皮肤等病损。部分OLP病损特别是糜烂型OLP可发生癌变，WHO将其列为口腔潜在恶性疾患 ［ 4 ］ 。Ramos-García等 ［ 5 ］ 通过荟萃分析发现，OLP的癌变率为0.44%~2.28%。OLP病因尚不明确，可能与免疫、感染、精神、内分泌等多种因素有关，此外还与多种系统性疾病有关，如糖尿病、甲状腺疾病、高血压、血脂异常、消化道功能紊乱等 ［ 6 , 7 , 8 , 9 , 10 , 11 ］ 。
OLP与自身免疫性疾病的关联逐渐成为国际研究热点和前沿。其中，桥本甲状腺炎（Hashimoto thyroiditis，HT）是一种常见的器官特异性自身免疫病 ［ 12 ］ 。普通人群中HT的患病率为0.4%~2.0%，女性患病率是男性的7~10倍 ［ 13 ］ 。甲状腺过氧化物酶抗体（thyroid peroxidase antibody，TPOAb）和甲状腺球蛋白抗体（thyroglobulin antibody，TGAb）是甲状腺特异性抗体，与HT密切相关，HT患者中TPOAb的阳性率约为95%，TGAb的阳性率为60%∼80% ［ 14 ］ 。随着HT的发展，其可影响甲状腺功能，导致促甲状腺激素、游离三碘甲状腺原氨酸、游离甲状腺素、三碘甲状腺原氨酸、甲状腺素水平改变，疾病后期约有50%的患者表现为甲状腺功能减退 ［ 15 ］ 。还有研究显示HT是甲状腺乳头状癌的独立危险因素 ［ 16 , 17 , 18 ］ 。现有研究关于OLP与HT的相关性存在争议。Li等 ［ 19 ］ 通过荟萃分析发现，OLP患者中甲状腺疾病的患病率显著高于健康人群。Lo Muzio等 ［ 20 ］ 研究发现，OLP患者中HT的患病率为14.3%，而一般人群中HT的患病率为2%。但也有部分学者持反对意见。Kats等 ［ 21 ］ 发现OLP与甲状腺疾病之间不存在显著相关性。Fatemeh和Marjan ［ 22 ］ 通过回顾性研究发现，OLP与甲状腺功能减退症之间无显著相关性。
本课题组前期研究发现，OLP患者特别是女性OLP患者HT患病率显著高于普通人群，但OLP的临床表现与HT、TPOAb滴度或TGAb滴度均无显著相关性 ［ 23 ］ 。然而，HT和OLP均涉及T细胞介导的免疫反应和慢性炎症过程，两者可能存在共同的免疫病理机制 ［ 24 ］ 。TPOAb和TGAb作为甲状腺自身免疫标志物，反映了全身性免疫功能失调的状态，失调的免疫系统可能通过细胞因子、免疫细胞活性等途径间接影响OLP疗效。OLP具有反复发作的特点，尚无根治方案。对于OLP伴HT的患者，常规治疗方案的疗效尚不明确。本研究拟通过定性、定量研究初步探讨血清甲状腺抗体TPOAb和TGAb与OLP临床疗效的关系，以期为OLP伴甲状腺抗体阳性患者个性化治疗方案的选择提供借鉴和依据。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
中华口腔医学会口腔黏膜病学专业委员会,中华口腔医学会中西医结合专业委员会. 口腔扁平苔藓诊疗指南(修订版)[J]. 中华口腔医学杂志, 2022,57(2):115-121. DOI: 10.3760/cma.j.cn112144-20211115-00505 .
返回引文位置Google Scholar
百度学术
万方数据
Society of Oral Medicine,Chinese Stomatological Association,Society of Traditional Chinese Medicine Combined with Western Medicine,Chinese Stomatological Association. Guideline for the diagnosis and treatment of oral lichen planus (revision)[J]. Chin J Stomatol, 2022,57(2):115-121. DOI: 10.3760/cma.j.cn112144-20211115-00505 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[2]
Li C , Tang X , Zheng X ,et al. Global prevalence and incidence estimates of oral lichen planus: a systematic review and meta-analysis[J]. JAMA Dermatol, 2020,156(2):172-181. DOI: 10.1001/jamadermatol.2019.3797 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Cassol-Spanemberg J , Rodríguez-de Rivera-Campillo ME , Otero-Rey EM ,et al. Oral lichen planus and its relationship with systemic diseases. A review of evidence[J]. J Clin Exp Dent, 2018,10(9):e938-e944. DOI: 10.4317/jced.55145 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Muller S , Tilakaratne WM . Update from the 5th edition of the World Health Organization classification of head and neck tumors: tumours of the oral cavity and mobile tongue[J]. Head Neck Pathol, 2022,16(1):54-62. DOI: 10.1007/s12105-021-01402-9 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Ramos-García P , González-Moles MÁ , Warnakulasuriya S . Oral cancer development in lichen planus and related conditions-3.0 evidence level: a systematic review of systematic reviews[J]. Oral Dis, 2021,27(8):1919-1935. DOI: 10.1111/odi.13812 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Alrashdan MS , Cirillo N , McCullough M . Oral lichen planus: a literature review and update[J]. Arch Dermatol Res, 2016,308(8):539-551. DOI: 10.1007/s00403-016-1667-2 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Deng X , Wang Y , Jiang L ,et al. Updates on immunological mechanistic insights and targeting of the oral lichen planus microenvironment[J]. Front Immunol, 2022,13:1023213. DOI: 10.3389/fimmu.2022.1023213 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Louisy A , Humbert E , Samimi M . Oral lichen planus: an update on diagnosis and management[J]. Am J Clin Dermatol, 2024,25(1):35-53. DOI: 10.1007/s40257-023-00814-3 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
El-Howati A , Thornhill MH , Colley HE ,et al. Immune mechanisms in oral lichen planus[J]. Oral Dis, 2023,29(4):1400-1415. DOI: 10.1111/odi.14142 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Mehrbani SP , Motahari P , Azar FP ,et al. Role of interleukin-4 in pathogenesis of oral lichen planus: a systematic review[J]. Med Oral Patol Oral Cir Bucal, 2020,25(3):e410-e415. DOI: 10.4317/medoral.23460 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Manchanda Y , Rathi SK , Joshi A ,et al. Oral lichen planus: an updated review of etiopathogenesis, clinical presentation, and management[J]. Indian Dermatol Online J, 2024,15(1):8-23. DOI: 10.4103/idoj.idoj_652_22 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Tywanek E , Michalak A , Świrska J ,et al. Autoimmunity, new potential biomarkers and the thyroid gland: the perspective of Hashimoto's thyroiditis and its treatment[J]. Int J Mol Sci, 2024,25(9):4703. DOI: 10.3390/ijms25094703 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Klubo-Gwiezdzinska J , Wartofsky L . Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment[J]. Pol Arch Intern Med, 2022,132(3):16222. [pii ] DOI: 10.20452/pamw.16222 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Rotondi M , Capelli V , Locantore P ,et al. Painful Hashimoto′s thyroiditis: myth or reality?[J]. J Endocrinol Invest, 2017,40(8):815-818. DOI: 10.1007/s40618-017-0655-5 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Uhliarova B , Hajtman A . Hashimoto′s thyroiditis: an independent risk factor for papilla ry carcinoma [J]. Braz J Otorhinolaryngol, 2018,84(6):729-735. DOI: 10.1016/j.bjorl.2017.08.012 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Marongiu A , Nuvoli S , De Vito A ,et al. Hashimoto′s thyroiditis and papillary thyroid carcinoma: a follow-up study in patients with absence of aggressive risk factors at the surgery of the primary tumor[J]. Diagnostics (Basel), 2023,13(19):3068. DOI: 10.3390/diagnostics13193068 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Ahmed R , Al-Shaikh S , Akhtar M . Hashimoto thyroiditis: a century later[J]. Adv Anat Pathol, 2012,19(3):181-186. DOI: 10.1097/PAP.0b013e3182534868 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Sulaieva O , Selezniov O , Shapochka D ,et al. Hashimoto′s thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links[J]. Heliyon, 2020,6(1):e03077. DOI: 10.1016/j.heliyon.2019.e03077 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Li D , Li J , Li C ,et al. The association of thyroid disease and oral lichen planus: a literature review and meta-analysis[J]. Front Endocrinol (Lausanne), 2017,8:310. DOI: 10.3389/fendo.2017.00310 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Lo Muzio L , Santarelli A , Campisi G ,et al. Possible link between Hashimoto′s thyroiditis and oral lichen planus: a novel association found[J]. Clin Oral Investig, 2013,17(1):333-336. DOI: 10.1007/s00784-012-0767-4 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Kats L , Goldman Y , Kahn A ,et al. Oral lichen planus and thyroid gland diseases: possible associations[J]. BMC Oral Health, 2019,19(1):169. DOI: 10.1186/s12903-019-0859-5 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Fatemeh L , Marjan M . Evaluation of the association between oral lichen planus and hypothyroidism: a retrospective comparative study[J]. J Dent (Shiraz, Iran), 2016,17(1):38-42.
返回引文位置Google Scholar
百度学术
万方数据
[23]
Zhang T , Hou F , Liu D ,et al. Association of Hashimoto′s thyroiditis and anti-thyroid antibodies with oral lichen planus: a cross-sectional study[J]. Front Immunol, 2022,13:967988. DOI: 10.3389/fimmu.2022.967988 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
王雅慧,郝一龙,唐帆,等. 口腔扁平苔藓与自身免疫性甲状腺疾病共存的免疫机制探讨[J]. 浙江大学学报(医学版), 2021,50(2):222-228. DOI: 10.3724/zdxbyxb-2021-0124 .
返回引文位置Google Scholar
百度学术
万方数据
Wang YH , Hao YL , Tang F ,et al. Immune mechanisms involved in the coexistence of oral lichen planus and autoimmune thyroid diseases[J]. J Zhejiang Univ (Med Sci), 2021,50(2):222-228. DOI: 10.3724/zdxbyxb-2021-0124 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[25]
Wu Y , Xu H , Wang Y ,et al. An improved scoring system for monitoring oral lichen planus: a preliminary clinical study[J]. Oral Dis, 2023,29(8):3337-3345. DOI: 10.1111/odi.14273 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
DeAngelis LM , Cirillo N , McCullough MJ . The immunopathogenesis of oral lichen planus-Is there a role for mucosal associated invariant T cells?[J]. J Oral Pathol Med, 2019,48(7):552-559. DOI: 10.1111/jop.12898 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Lodi G , Scully C , Carrozzo M ,et al. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2005,100(1):40-51. DOI: 10.1016/j.tripleo.2004.06.077 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Petranović Ovčariček P , Görges R , Giovanella L . Autoimmune thyroid diseases[J]. Semin Nucl Med, 2024,54(2):219-236. DOI: 10.1053/j.semnuclmed.2023.11.002 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Wu P , Luo S , Zhou T ,et al. Possible mechanisms involved in the cooccurrence of oral lichen planus and Hashimoto′s thyroiditis[J]. Mediators Inflamm, 2020,2020:6309238. DOI: 10.1155/2020/6309238 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
汤云居,沈雪敏. 口腔扁平苔藓伴发桥本甲状腺炎的发病机制研究进展[J]. 临床口腔医学杂志, 2019,35(4):245-247. DOI: 10.3969/j.issn.1003-1634.2019.04.017 .
返回引文位置Google Scholar
百度学术
万方数据
Tang YJ , Shen XM . Research progress on the pathogenesis of Hashimoto′s thyroiditis associated with oral lichen planus[J]. J Clin Stomatol, 2019,35(4):245-247. DOI: 10.3969/j.issn.1003-1634.2019.04.017 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[31]
苏葵,胥红. 胸腺肽对口腔扁平苔藓患者相关细胞因子影响的研究[J]. 实用口腔医学杂志, 2014,30(3):429-431.
返回引文位置Google Scholar
百度学术
万方数据
Su K , Xu H . The effects of thymopeptides enteric-coated tablets on oral lichen planus and the expression of related cytokines[J]. J Pract Stomatol, 2014,30(3):429-431.
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
备注信息
A
陈谦明，Email： nc.defudabe.ujznehcmq，电话：0571-87217001
B

刘传霞：文章撰写；陈方曼：数据统计分析；张珊珊：文献查阅、临床资料收集；唐帆：文献查阅、课题设计；章尚君：临床资料收集；钱韵：临床资料收集；陈谦明：课题设计指导、对文章的知识性内容作批评性审阅

C

美国临床试验注册中心（NCT05403216）

D
刘传霞, 陈方曼, 张珊珊, 等. 血清甲状腺抗体对口腔扁平苔藓治疗方案选择意义的初步探讨[J]. 中华口腔医学杂志, 2025, 60(3): 223-231. DOI: 10.3760/cma.j.cn112144-20241216-00487.
E
所有作者声明不存在利益冲突
F
浙江省卫生健康重大科技计划项目 (WKJ-ZJ-2212)
国家自然科学基金 (82330029)
浙江省科技计划项目 (2024C03193)
浙江省教育厅一般科研项目 (Y202353386)
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
供瓣区选择与修复策略的初步探讨
韩军涛 等
中华烧伤杂志 2020,36(02)
抗甲状腺药物治疗后Graves甲亢复发患者的治疗方案选择
刘梦思 等
中华内分泌代谢杂志 2019,35(10)
口腔扁平苔藓病损组织中白细胞介素35的表达及意义
王荣 等
中华口腔医学杂志 2018,53(01)
养阴益气合剂对口腔扁平苔藓患者血清及唾液干扰素γ和白细胞介素10水平的影响及临床意义
周淑珍 等
中国基层医药 2016,23(22)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大